Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CD19-CAR-Lenti_ALLO |
Trade Name | |
Synonyms | CD19-CAR_Lenti_ALLO |
Drug Descriptions |
CD19-CAR-Lenti_ALLO comprises allogeneic T-cells engineered with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting CD19 and containing the TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (PMID: 37172203). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CD19-CAR-Lenti_ALLO | CD19-CAR-Lenti_ALLO | 0 | 1 |